Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Recruiting
Observational Study
Cardiotoxicity
Pediatric Cancer
Heart Failure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 13 – 39
- Sex
- Any
- Study type
- Observational
- Participants needed
- 150 (estimated)
- Sponsor
- Hari Narayan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart f…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* English and Spanish speaking male and female subjects, ages 13-39 years old
* Diagnosis of cancer at age \<22 years
* Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.
Exclusion Criteria:
* Patients who have a contraindication …
Contacts